Cardiology
RSSArticles
-
A Review of Current Therapeutics for Severe COVID-19 Pneumonia
The aim of this special feature is to review therapeutic options for hospitalized patients with COVID-19 pneumonia.
-
A New Treatment for Refractory Hyperlipidemia
In patients with familial hypercholesterolemia who are not at target LDL cholesterol levels on maximum-tolerated doses of statins and PCSK9 inhibitors, evinacumab, which inhibits angiopoietin-like 3, reduces LDL by more than 50% at the highest doses with few side effects requiring drug discontinuation vs. placebo.
-
Expanding Uses for Direct Oral Anticoagulants: Bioprosthetic Heart Valves?
A randomized, controlled trial of rivaroxaban vs. warfarin in patients with atrial fibrillation and a bioprosthetic valve revealed rivaroxaban is noninferior to warfarin for the prevention of major cardiovascular events and the avoidance of major bleeding events over 12 months.
-
Time is of the Essence with Colchicine Treatment of Myocardial Infarction
An analysis of the COLCOT study of colchicine administration after myocardial infarction (MI) showed the benefit of this therapy for preventing subsequent cardiovascular events was greatest when therapy was initiated within three days after MI onset.
-
Left Ventricular Size, Function Predictors of Outcomes in Chronic Aortic Regurgitation
In a large cohort of asymptomatic patients with hemodynamically significant chronic aortic regurgitation, volumetric left ventricular size and function measurements were equally discriminant in identifying patients at higher risk for mortality vs. traditional linear measurements.
-
What Causes MINOCA?
A systematic imaging protocol of coronary angiography, optical coherence tomography, and cardiac MRI in women clinically diagnosed with myocardial infarction with non-obstructive coronary artery disease revealed a cause in 84%, with three-quarters exhibiting an ischemic etiology.
-
Must-Have Documentation if ‘Low-Risk’ Chest Pain Patient Is Discharged from ED
Documenting an assessment with a validated scoring system and ensuring the timing of troponins is appropriate can reduce risk.
-
Is There Bundle Branch Block?
Try to interpret the ECG in the figure without the benefit of any clinical information. What do you see?
-
Bamlanivimab Injection
Bamlanivimab is a neutralizing recombinant IgG1 monoclonal antibody that connects to the receptor-binding domain of the spike protein of SARS-CoV-2. The drug blocks attachment and entry of the virus into human cells.
-
When Aortic Stenosis Is Almost Severe: What Happens Next?
A study of patients with normal flow, low gradients, normal left ventricular systolic function but with calculated aortic valve areas <1.0 cm2 showed that about half of them progressed to severe aortic stenosis during the 25-month median follow-up period.